Xofluza was approved in China
2021-05-13
On April 29, 2021, Roche China announced that its innovative influenza drug Xofluza® (Mabaloxavir) has been formally approved by NMPA for the treatment of 12 Acute and uncomplicated influenza patients who are one year old and above, including those who are at high risk of influenza complications.
Baloxavirr is an innovative cap-shaped structure-dependent endonuclease inhibitor. It is currently the first and only single-dose oral drug approved for the treatment of influenza. Mabaloxavir only needs to take the medicine once in the whole course, which can stop the virus detoxification within 24 hours, shorten the infectious period and greatly reduce the duration of flu symptoms, and bring more convenient treatment options for patients.
